Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

Julie Hambleton Biography and Net Worth

Director of IGM Biosciences

Dr. Hambleton also serves on the Board of Directors at Accent Therapeutics, SpringWorks Therapeutics and at Arch Oncology where she was also Interim Chief Executive Officer. Previously, she was the Chief Medical Officer and Head of Development at IDEAYA Biosciences, an oncology medicine company. Prior to IDEAYA, she was Vice President and Head of U.S. Medical at Bristol-Myers Squibb. She has also served as Executive Vice President and Chief Medical Officer at Five Prime Therapeutics, Vice President of Clinical Development at Clovis Oncology, and held increasing roles of responsibility in BioOncology at Roche/Genentech, most recently as Global Cluster Head and Global Group Medical Director. Dr. Hambleton completed her hematology-oncology training at the University of California, San Francisco, and served on the faculty there from 1993 to 2003. Dr. Hambleton received a B.S. in Nursing from Duke University and an M.D. from Case Western Reserve University School of Medicine. She is board-certified in Hematology and Internal Medicine.

What is Julie Hambleton's net worth?: The estimated net worth of Julie Hambleton is at least $33,883.92 as of July 19th, 2023. Ms. Hambleton owns 4,648 shares of IGM Biosciences stock worth more than $33,884 as of April 19th. This net worth evaluation does not reflect any other investments that Ms. Hambleton may own. Learn More about Julie Hambleton's net worth.
How do I contact Julie Hambleton?: The corporate mailing address for Ms. Hambleton and other IGM Biosciences executives is 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. IGM Biosciences can also be reached via phone at 650-965-7873. Learn More on Julie Hambleton's contact information.
Has Julie Hambleton been buying or selling shares of IGM Biosciences?: Julie Hambleton has not been actively trading shares of IGM Biosciences during the last ninety days. Most recently, Julie Hambleton sold 1,000 shares of the business's stock in a transaction on Monday, August 9th. The shares were sold at an average price of $80.00, for a transaction totalling $80,000.00. Learn More on Julie Hambleton's trading history.
Who are IGM Biosciences' active insiders?: IGM Biosciences' insider roster includes Daniel Chen (Insider), Julie Hambleton (Director), and Bruce Keyt (Insider). Learn More on IGM Biosciences' active insiders.
Are insiders buying or selling shares of IGM Biosciences?: During the last twelve months, IGM Biosciences insiders bought shares 6 times. They purchased a total of 858,796 shares worth more than $6,506,589.47. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 39,921 shares worth more than $276,856.74. The most recent insider tranaction occured on March, 28th when Director Bros. Advisors Lp Baker bought 97,473 shares worth more than $937,690.26. Insiders at IGM Biosciences own 56.9% of the company. Learn More about insider trades at IGM Biosciences.
Information on this page was last updated on 3/28/2024.

Julie Hambleton Insider Trading History at IGM Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/9/2021	Sell	1,000	$80.00	$80,000.00
6/1/2021	Sell	2,000	$80.00	$160,000.00	3,000

Julie Hambleton Buying and Selling Activity at IGM Biosciences

IGM Biosciences Company Overview

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Today's Range

Now: $7.29

$7.04

$7.43

50 Day Range

MA: $11.33

$7.41

$17.36

2 Week Range

Now: $7.29

$3.81

$17.70

Volume

128,904 shs

Average Volume

276,149 shs

Market Capitalization

$428.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.26

Bitcoin Rockets To Record High But Buy THIS Instead

From Paradigm Press | Ad